Dec 27, 2022
By: Vaamanaa SethiBharat Biotech’s iNCOVACC is the first approved intranasal vaccine in the world. The vaccine will be available in the Indian market by the fourth week of January 2023.
Credit: Bharat-Biotech
The Indian health ministry said that those who have taken Covishield and Covaxin could take the nasal vaccine as a booster dose.
Credit: BCCL
On Tuesday, December 27, the Centre approved the cost of the vaccine - ₹800 for private hospitals and ₹325 for government ones.
Credit: Unsplash
World's first intranasal vaccine for COVID got approval from the Central Drugs Standard Control Organisation (CDSCO) last week. It has received both primary series and heterologous booster approval.
Credit: BCCL
The vaccine had earlier got restricted approval - only to be used in emergency situations for people aged 18 and above for a primary 2-dose schedule, according to news agency ANI.
Credit: Unsplash
Those who are over 18 years old and have already received two doses of Covid-19 vaccine can get this vaccine as a booster dose in India.
Credit: Unsplash
It is a non-invasive, needle-free vaccine, which will be administered through the nose. The doctor will spray the vaccine into nostrils with a small syringe that has no needle.
Credit: Unsplash
According to media reports, the vaccine will take at least two weeks to start working on one’s body. It leads to the immune system forming proteins in the blood and nose which helps in fighting the virus.
Credit: Unsplash
We have developed COVAXIN and iNCOVACC, two Covid vaccines from two different platforms, with two different delivery systems,” Dr. Krishna Ella, executive chairman, Bharat Biotech, told IANS.
Credit: Bharat-Biotech